NICE Endorses Talazoparib Enzalutamide for Pros...

By HEOR Staff Writer

January 23, 2026

NICE Backs Talazoparib-Enzalutamide for Advanced Prostate Cancer The National Institute for Health and Care Excellence (NICE) has recommended talazoparib enzalutamide ...
Sandoz Biosimilars Strategy: Capturing Market Opportunities for Affordable He...
Alzheimer’s Care Innovation: Advancing Implementation Across Europe
Navigating Economic Resilience Through Life Sciences Investment
EU Medicine Authorizations 2025: A Milestone for Innovation and Accessibility
Guiding Principles for Ethical AI Integration in Drug Development
EU Launches Joint Scientific Consultations to Enhance Health Technology Asses...
Epidyolex Spending in Portugal Exceeds €3 Million Amid Regulatory Delays
Empowering Leaders at the Global Pharma Executive Course: Navigating Industry...
NHS Cost-Effectiveness Thresholds Boost Drug Approvals and Innovation
NICE Endorses Natalizumab RRMS Treatment Expansion for Refractory Cases
Johnson & Johnson’s EMA Application for Teclistamab Daratumumab Th...
INFARMED Leadership Appointments: A New Era in Health Regulation and Expertise